> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Testicular Cancer Makes Up More Than Half Of Fennec's Business As It Pursues Adult Evidence
- URL: https://www.bullished.co/testicular-cancer-makes-up-more-than-half-of-fennecs-business-as-it-pursues-adult-evidence-2f22ca5f/
- Published: 2026-11-12T14:33:13.000Z
- Updated: 2026-11-12T14:33:13.000Z
- Description: Management would not predict a 2027 guideline change; City of Hope plans to present interim adult-study findings in early January.
- Author: Matteo Parrino
- Tags: Earnings, FENC, Industry: Healthcare

Testicular cancer accounts for more than half of Fennec Pharmaceuticals' business, Chief Financial Officer Robert Andrade said on Thursday's earnings call. Fennec, which sells medicine to reduce chemotherapy-related hearing loss in children, is funding independent research into older adults and metastatic disease.

## Adult Evidence Comes Before Guidelines

Andrade described testicular cancer as "a little north of half of our business today" and said the company has further opportunities to reach those patients, who receive substantial exposure to cisplatin chemotherapy.

PEDMARK, Fennec's central product, is an intravenous medicine for children with solid tumors that have not spread. Its research program is examining hearing protection across additional cancers and patient groups, under a strategy established in the fourth quarter of 2025.

Jeff Hackman, Fennec's Chief Executive Officer and Board Member, said the independent studies address physicians' questions about use beyond adolescents and young adults. His position on older adults and metastatic disease was direct: "we want to see the data".

An H.C. Wainwright analyst asked whether an adult recommendation from the National Comprehensive Cancer Network could come before the end of 2027\. Hackman answered: "We can never project anything like that."

City of Hope Cancer Center plans to present interim findings in early January from its independent study in adult men with stage 2 and 3 metastatic testicular germ cell tumors. It also plans to present findings on practical treatment delivery and observed toxicity using patient-support-program records for adults with germ cell tumors receiving platinum-based chemotherapy.

A Japanese mid-stage study in children, adolescents and young adults with non-metastatic tumors supplies another strand of evidence. Fennec's Thursday earnings release said results presented at a scientific meeting showed [significant hearing protection](https://www.globenewswire.com/news-release/2026/11/12/3401343/0/en/fennec-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co).

## Hundreds Of Potential Academic-Center Patients

Fennec recently secured permission for physicians at a large Midwestern academic center and its home-infusion service to prescribe PEDMARK. Andrade said that access could reach hundreds of patients, but clarified that the win was not a major third-quarter revenue contributor.

Hackman said use at the center was gaining ground in October and November. He attributed the access win to coordinated work by commercial staff, market-access specialists and medical science liaisons, including engagement with influential physicians.

Fennec expanded its sales organization in the first quarter with 14 territories and four frontline managers. Its physician-and-account targets increased from about 1,300 to 5,000\. Data from community-practice partners also helps the team identify patients who may qualify for treatment.

The U.S. business uses a pediatric oncology sales team and a patient support program that helps with insurance, financial assistance and treatment access. Outside the U.S., commercialization partner Norgine sells the medicine as PEDMARQSI; it launched in Germany and the U.K. during 2025.

## Sales Growth Funds The Research Push

Third-quarter net product sales rose approximately 56% to [$19.4 million](https://www.globenewswire.com/news-release/2026/11/12/3401343/0/en/fennec-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) from $12.5 million a year earlier. Patient-program enrollments increased 23%, and completed infusions rose 58%; Andrade said enrollment timing, infusion timing and patient mix affect how those measures translate into revenue.

Adjusted earnings before interest, taxes, depreciation and amortization reached about $5.8 million, against $2 million a year earlier and $2.8 million in the second quarter. Earnings were $0.12 per share, compared with a $0.02 loss a year earlier.

Fennec generated nearly $7 million in operating cash and ended September with $48.7 million in cash and equivalents and no debt. Research and selling, general and administrative expenses excluding stock-based pay were about $12.7 million, up about $3 million; management expects fourth-quarter cash operating expenses to be the year's lowest.

Fennec is also in active licensing discussions for Japan. Hackman said speed of patient access matters, but he would not accept a deal unfavorable to Fennec.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Fennec Pharmaceuticals Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/12/3401343/0/en/fennec-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com